Navigation Links
Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
Date:11/18/2009

PITTSBURGH, Nov. 18 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Didier Barret, president of Mylan Europe, Middle East and Africa (EMEA), has been elected president of the European Generic Medicines Association (EGA). Barret was elected to a two-year term earlier today at the EGA annual meeting being held in Brussels.

Mylan Chairman and CEO Robert J. Coury said: "We are extremely pleased to have one of our own senior executives lead Europe's generic trade organization over the next two years. The EGA could not have elected a stronger leader to help guide our industry in Europe than Didier Barret. His willingness to serve EGA in this capacity emphasizes Mylan's commitment to enhance industry efforts in international markets as generic pharmaceuticals represent a proven and successful solution to rising global health care costs."

Commenting on his appointment Barret said: "I am very proud to be able to serve EGA as president. One of my goals is to replicate the kind of strong collaboration that Mylan has had with the industry associations across the world. I also look forward to continuing to help shape the European generics marketplace as a facilitator between the industry and our colleagues at health care agencies across the different European regions. Creating conditions for a sustainable and competitive generics industry within the European market will be a priority for EGA in the years ahead."

The EGA is the official representative body of the European generic and bio-similar pharmaceutical industry, which is at the forefront of providing high quality affordable medicines to millions of Europeans and stimulating competitiveness and innovation in the pharmaceutical sector. Formed in 1993, the EGA represents generic pharmaceuticals companies and their subsidiaries throughout Europe, either directly or through national associations.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexington International, LLC Receives 2009 U.S. Presidents E Award Recognizing its Export Achievements
2. IDEV Technologies Names Christopher M. Owens President, Chief Executive Officer
3. Voler Systems President Speaks at BIOMEDevice San Jose
4. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
5. Gary Wenzel Named President TBWA\WorldHealth
6. Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
7. VIVUS Announces Promotion of Peter Tam to President
8. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
9. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
10. ClinOps, LLC Enhances Senior Management Team With Addition of Connie Andrews as Senior Vice President of Clinical Operations
11. Csuy Named Senior Vice President/General Merchandise Manager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016  Kindred Biosciences, ... on saving and improving the lives of pets, today ... Section of the New Animal Drug Application (NADA) for ... pivotal field study (KB0120) of Zimeta for the control ... the Company. --> --> ...
(Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... Sun City is the place to be on March 3rd to learn about the latest ... hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will be presented ... addition, prizes will be given away and light refreshments will be served. , As ...
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased ... has delved into this niche allowing those giving up their beloved pasta a chance ... grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or ... groom themselves to perfection, go out of their way to be romantic, and may ... take a look at any online dating profile. , A recent study from ...
(Date:2/12/2016)... San Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... of love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. ... in fact a love story, the love of a Buddhist teacher for teaching and ...
Breaking Medicine News(10 mins):